News - Cervarix, GlaxoSmithKline

Filter

Current filters:

CervarixGlaxoSmithKline

Popular Filters

FDA “Breakthrough Therapy” designation for GSK’s malaria drug tafenoquine; EU Cervarix news

FDA “Breakthrough Therapy” designation for GSK’s malaria drug tafenoquine; EU Cervarix news

22-12-2013

The US Food and Drug Administration has granted “Breakthrough Therapy” designation for tafenoquine,…

CervarixEuropeGlaxoSmithKlineNorth AmericaPharmaceuticalRegulationtafenoquineTropical diseases

CHMP positive opinion for GSK’s Cervarix two-dose schedule

CHMP positive opinion for GSK’s Cervarix two-dose schedule

28-11-2013

UK pharma giant GlaxoSmithKline says that the European Medicines Agency's Committee for Medicinal Products…

CervarixEuropeGlaxoSmithKlineOncologyPharmaceuticalRegulationVaccines

Merck’s new HPV vaccine could rejuvenate market, says GlobalData

Merck’s new HPV vaccine could rejuvenate market, says GlobalData

18-11-2013

Despite being hampered both by apathy and resistance in recent years, the human papillomavirus (HPV)…

CervarixGardasilGlaxoSmithKlineMarkets & MarketingMerck & CoPharmaceuticalV503VaccinesWomen's Health

Uptake of HPV vaccines must increase to reap rewards

Uptake of HPV vaccines must increase to reap rewards

08-11-2013

Here's our take on the week's top stories.

CervarixGlaxoSmithKlineHealthcareMerck & CoOncologyPharmaceuticalVaccines

New data support GSK’s Cervarix two-dose schedule

New data support GSK’s Cervarix two-dose schedule

04-11-2013

UK pharma giant GlaxoSmithKline has revealed the results of a Phase III study of its HPV vaccine, Cervarix,…

CervarixGlaxoSmithKlineOncologyPharmaceuticalResearchVaccines

Slow uptake of HPV vaccine in USA "risks health of next generation"

29-07-2013

US human papillomavirus (HPV) vaccination rates in girls aged 13-17 years failed to increase between…

CervarixGardasilGlaxoSmithKlineHealthcareMerck & CoNorth AmericaPharmaceuticalVaccines

Japan vaccines briefs: Gardasil and Cervarix; Daiichi Sankyo files NDA

21-06-2013

The Japanese Ministry of Health, Labor and Welfare has decided to withdraw its recommendation for a vaccination…

Asia-PacificCervarixDaiichi SankyoGardasilGlaxoSmithKlineMerck & CoPharmaceuticalRegulationVaccinesWomen's Health

Merck & Co's Gardasil and GSK's Cervarix to be available to developing countries via UNICEF tender

09-05-2013

A new record low price for human papillomavirus (HPV) vaccines will help ensure millions of girls in…

CervarixGardasilGlaxoSmithKlineHealthcareMerck & CoOncologyPharmaceuticalPricingRest of the World

Adult vaccines market controlled by GSK and Merck

15-04-2013

The adult vaccines market has been forecast to increase at a compound annual growth rate (CAGR) of 5.6%…

CervarixGardasilGlaxoSmithKlineMarkets & MarketingMerck & CoPfizerPharmaceuticalPrevnarVaccines

GAVI Alliance funds vaccines for cervical cancer in developing countries

08-02-2013

More than 180,000 girls in eight developing countries are set to receive protection against the leading…

CervarixGardasilGlaxoSmithKlineHealthcareMerck & CoPharmaceuticalRest of the WorldVaccinesWomen's Health

UK government to switch from Cervarix to Gardasil for HPV vaccination

25-11-2011

As of next September, a different vaccine will be used in the HPV vaccination program to protect girls…

CervarixEuropeGardasilGlaxoSmithKlineHealthcareMerck & CoOncologyPharmaceuticalPricingSanofiSanofi Pasteur MSDVaccinesWomen's Health

Cancer vaccines market set to see change, will grow to over $9 billion by 2018

24-10-2011

The global cancer vaccines market in seven key markets (the USA, France, Germany, Italy, Spain, UK and…

CervarixDendreonGardasilGlaxoSmithKlineGlobalMarkets & MarketingMerck & CoOncologyPharmaceuticalProvengeVaccines

Cost benefit analysis of cervical cancer vaccines sees Gardasil beat Cervarix

29-09-2011

An analysis of cervical-cancer vaccine has shown that Merck & Co’s (NYSE: MRK) Gardasil (human papillomavirus…

CervarixEuropeGardasilGlaxoSmithKlineMerck & CoPharmaceuticalPricingVaccines

Back to top